1[1]Williams DO, Holubkov R, Yeh W, et al. Pereutaneous coronary intervention in the current era compared with 1985-1986: the National Heart, Lung, and Blood Institute Registries. Circulation, 2000, 102:2945-2951.
2[2]Mehran R, Dangas G, Abizaid AS, et al. Angiographic pattems of instent restenosis: classification and implacation for long-term outcome.Circulation, 1999,100:1872-1878.
3[3]Mehran R, Dangas G, Mintz GS, et al. In-stent restenosis: the great equalizer-disappointing clinical outcomes with all interventional strategies. J Am Coll Cardiol, 1999,33(suppl A):66A.
4[4]Hoffman R, Mintz GS, Dussaillant GR, et al. Pattems and mechanisms of in-stent restenosis: serial intravascular ultrasound study.Circulation, 1996,94:1247-1254.
5[5]Gregory BM, Huie P, Billingham ME , et al. Rapamycin inhibits arterial intimal thickening caused by both alloimmune and mechanical injury: its effect on cellular,growth factor, and cytokine response in injured vessels. Transplantation, 1993,55:1409-1418.
6[6]Gallo R, Padurean A, Jayaraman T, et al. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation, 1999, 99: 2164-2170.
7[7]Carter A J, Kopia G, Llanos G, et al. Stent based sirolimus delivery reduces neointimal proliferation in a porcine coronary model of restenosis. J Am Coll Cardiol, 2000,35(suppl):13.
8[8]Gregory CR, Katznelson S, Griffey SM, et al. Fluvastatin in combination with rad significantly reduce graft vascular disease in rat cardiac allografts. Transplantation, 2001,72:989-993.
9[9]Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature, 1979,277:665-667.
10[10]Axel DI, Kunert W, Goggelmann C, et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation, 1997,96:636-645.
4Sousa JE,Abizaid AC,et al.Late (two years) follow-up from the firstin-man experience after implantation of sirolimus-eluting stent.J Am Coll Cardiol,2002,39-21.
5Tanner EC,Yang ZY,Dukers E,et al.Expression of cylin dependent kinnase inhibitors in vascular disease.Circ Res,1998.83.
6Hausleiter J,Sebastion M,Li AN,et al.A porcine coronary stent model of increased neointima formation in the left anterior descending coronary artery.Z Kardiol,2002,91:614 ～619.
7Schwarts SM.Smooth muscle migration in atherosclerosis and restenosis.J Clin Invest,1997,100:587 ～ 589.
8Rogers C, Karnovsky M J, Edelrnan E R, et al. Inhibition of experimental neointimal hyperplasia and thrombosis depends on the type of vascular injury and the site of drug administration[ J]. Circulation, 1993,89:1215-- 1221.
9Vinod L, Song C X, Robert J L. Nanoparticle drug delivery system for restenosis. Advanced Drug Delivery Reviews,1997, 24 (1): 63～85.
10Whitesides G M, Grzybowski B. Self-assembly at all scales. Science, 2002, 295 (5 564): 2 418～2 421.
